Denali Therapeutics DNLI reported a first-quarter 2025 loss of 78 cents per share, wider than the Zacks Consensus Estimate of a loss of 71 cents. The company reported a loss of 68 cents in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results